“David VanGorden, candidate for Rancho Cucamonga City Council District 2, discusses infrastructure and growth planning as Rancho Cucamonga continues to grow. He is running against incumbent Kristine Scott and candidate DeJonae Shaw.” As Rancho Cucamonga continues to grow, residents are asking whether infrastructure—roads, services, and long-term planning—is keeping pace with development. City Council candidate David …
Konstantin Vision & Eyewear Center Expands Same-Day Glasses
Konstantin Vision & Eyewear Center expands same-day prescription glasses service in Manhattan, offering select New York City prescriptions through its on-site optical lab. NEW YORK, NY – Konstantin Vision & Eyewear Center has expanded its same-day prescription glasses service from its Manhattan location, giving New York City customers a faster option for select prescriptions without sacrificing …
Continue reading “Konstantin Vision & Eyewear Center Expands Same-Day Glasses”
Chronic Inflammatory Demyelinating Polyneuropathy Market Set for Significant Growth by 2036, Driven by Emerging Targeted Therapies and Rising Diagnosis Rates | DelveInsight
The Chronic Inflammatory Demyelinating Polyneuropathy market is expected to grow steadily across the 7MM during the forecast period (2026–2036), driven by increasing disease awareness, improving diagnostic capabilities, and the anticipated launch of emerging therapies such as Riliprubart (Sanofi), Batoclimab (Immunovant), and others. These novel therapies are expected to reshape the treatment landscape for this chronic …
Pulmonary Arterial Hypertension Market Set for Significant Growth by 2036, Driven by Emerging Targeted Therapies and Rising Diagnosis Rates | DelveInsight
The Pulmonary Arterial Hypertension market is expected to grow steadily across the 7MM, driven by increasing disease awareness, improving diagnostic capabilities, and the anticipated launch of emerging therapies such as ralinepag (United Therapeutics), PF-07868489 (Pfizer), RT234 (Respira Therapeutics), seralutinib (Gossamer Bio), and others. DelveInsight’s report, “Pulmonary Arterial Hypertension (PAH) Market Insight, Epidemiology, and Market Forecast–2036,” …
Minimal Residual Disease Pipeline Set for Strategic Expansion by 2026 with Emerging Immunotherapies and Precision Diagnostics Advancing Clinical Outcomes | DelveInsight
“Minimal Residual Disease Clinical Trial” Key Minimal Residual Disease companies such as Genentech, AmMax Bio, and Precigen Inc are at the forefront of Minimal Residual Disease innovation, leveraging cutting-edge platforms to develop therapies that target residual disease with high precision. Minimal Residual Disease is rapidly emerging as a critical determinant of long-term cancer outcomes, with …
Cervical Dystonia Market Set for Significant Growth by 2036, Driven by Emerging Therapies and Increasing Diagnosis Rates | DelveInsight
The Cervical Dystonia market is expected to grow steadily across the 7MM during the forecast period (2026–2036), driven by increasing disease awareness, improving diagnosis rates, and the anticipated launch of emerging therapies such as ABP-450 (AEON Biopharma) and IPN10200 (Ipsen), among others. These novel therapies are expected to reshape the treatment landscape for this neurological …
Hearing Loss Pipeline Demonstrates Strong Clinical Momentum with 35+ Therapies Across 30+ Companies, Advancing Toward Next-Generation Auditory Restoration | DelveInsight
“Hearing Loss Clinical Trial” Key Hearing Loss Companies include Sensorion, AudioCure Pharma GmbH, Acousia Therapeutics, Neuracle Science, Regeneron Pharmaceuticals, Sound Pharmaceuticals, PAEAN Biotechnology, and others The Hearing Loss therapeutic landscape is undergoing a significant transformation, driven by robust clinical innovation and increasing investment from leading pharmaceutical and biotechnology companies. Organizations such as Sensorion, Acousia Therapeutics, …
Lipodystrophy Pipeline Set for Strategic Expansion by 2026 with 8+ Emerging Therapies and Advancing Clinical Programs Led by Regeneron Pharmaceuticals | DelveInsight
“Lipodystrophy Clinical Trial” Emerging Lipodystrophy therapeutic approaches include leptin receptor agonists, apolipoprotein C-III inhibitors, angiopoietin-like protein 3 (ANGPTL3) antagonists, and gene-based therapies. Lipodystrophy companies such as Regeneron Pharmaceuticals and other emerging biotech innovators are actively reshaping the therapeutic landscape through targeted drug development and next-generation metabolic interventions. With a growing emphasis on addressing underlying adipose …
Hypertriglyceridemia Pipeline Gains Significant Momentum with 20+ Therapies Across 18+ Companies, Advancing Novel Lipid-Modulating and Gene-Based Approaches | DelveInsight
“Hypertriglyceridemia Pipeline” Key Hypertriglyceridemia companies such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals are leveraging advanced technologies such as RNA interference and antisense platforms to develop highly targeted therapies. Hypertriglyceridemia companies such as NorthSea Therapeutics, Arrowhead Pharmaceuticals, Zhejiang Doer Biologics, Ionis Pharmaceuticals, GeneCradle, MediciNova, Regeneron Pharmaceuticals, and others are actively transforming the treatment landscape …
Von Willebrand’s Disease Pipeline Gains Momentum with Next-Generation Hemostatic Therapies and Advancing Clinical Assets from Star Therapeutics, Hemab, and Vega Therapeutics | DelveInsight
“Von Willebrand’s Disease Clinical Trial” Key Von Willebrand’s Disease Companies include Star Therapeutics, Hemab, Vega Therapeutics, and others The Von Willebrand’s Disease (VWD) therapeutic landscape is entering a phase of strategic transformation, driven by increasing research investments, novel biologic approaches, and a growing emphasis on targeted hemostatic therapies. Companies such as Star Therapeutics, Hemab, and …